Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML

Leukemia. 2005 Nov;19(11):1991-2. doi: 10.1038/sj.leu.2403931.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Core Binding Factor Alpha 2 Subunit
  • DNA-Binding Proteins / genetics*
  • Drug Resistance, Neoplasm / genetics
  • Genes, abl
  • Genetic Variation
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Male
  • Middle Aged
  • Piperazines / therapeutic use*
  • Point Mutation
  • Proto-Oncogene Proteins / genetics*
  • Pyrimidines / therapeutic use*
  • Transcription Factors / genetics*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Core Binding Factor Alpha 2 Subunit
  • DNA-Binding Proteins
  • Piperazines
  • Proto-Oncogene Proteins
  • Pyrimidines
  • RUNX1 protein, human
  • Transcription Factors
  • Imatinib Mesylate